Get the Stockscreener App
0.9949
0.01%
0.000100
After Hours:
1.00
0.0051
+0.51%
Century Therapeutics Inc stock is traded at $0.9949, with a volume of 1.94M.
It is up +0.01% in the last 24 hours and up +87.22% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.9948
Open:
$0.97
24h Volume:
1.94M
Relative Volume:
1.55
Market Cap:
$86.96M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.4345
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
-8.30%
1M Performance:
+87.22%
6M Performance:
+79.26%
1Y Performance:
-4.34%
1-Day Range:
$0.9064
$1.05
1-Week Range:
$0.9064
$1.09
52-Week Range:
$0.3418
$1.185
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.9949 | 86.95M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Critical Analysis: EOM Pharmaceutical (OTCMKTS:IMUC) & Century Therapeutics (NASDAQ:IPSC) - Defense World
Trend Report: Is Century Therapeutics Inc stock attractive after correctionJuly 2025 Update & Expert-Curated Trade Recommendations - moha.gov.vn
Street Watch: Why Century Therapeutics Inc stock is rated strong buyJuly 2025 Macro Moves & Safe Entry Trade Reports - moha.gov.vn
Chad Cowan Buys 58,060 Shares of Century Therapeutics (NASDAQ:IPSC) Stock - MarketBeat
Century Therapeutics announces resignation of board member - TipRanks
Century Therapeutics Announces Board Resignation - TradingView — Track All Markets
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MSN
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Significant Decrease in Short Interest - MarketBeat
What sentiment indicators say about Century Therapeutics Inc. stockJuly 2025 Review & Fast Entry Momentum Alerts - DonanımHaber
Can Century Therapeutics Inc. stock surprise with earnings upsideMarket Weekly Review & Weekly High Momentum Picks - DonanımHaber
Will Century Therapeutics Inc. stock benefit from infrastructure spendingStop Loss & Advanced Technical Signal Analysis - DonanımHaber
Will Century Therapeutics Inc. stock deliver better than expected guidance2025 Geopolitical Influence & Weekly Watchlist for Hot Stocks - DonanımHaber
Can Century Therapeutics Inc. stock reach $100 price targetMarket Performance Recap & Expert Curated Trade Ideas - DonanımHaber
Century Therapeutics adds veteran deal-makers to board as pipeline nears clinic - MSN
Why Century Therapeutics Inc. stock is popular among millennialsRisk Management & Target Return Focused Stock Picks - DonanımHaber
There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise - simplywall.st
Brent Pfeiffenberger Purchases 52,000 Shares of Century Therapeutics (NASDAQ:IPSC) Stock - MarketBeat
Century Therapeutics CEO Brent Pfeiffenberger Acquires 52,000 Shares - TradingView — Track All Markets
Century Therapeutics (IPSC) CEO and director reports 52,000-share buy - Stock Titan
Century Therapeutics Adds Veteran Deal-Makers to Board as Pipeline Nears Clinic - MyChesCo
Century Therapeutics (NASDAQ:IPSC) Trading Up 2.5% – Still a Buy? - Defense World
Century Therapeutics Earnings Notes - Trefis
[Form 4] Century Therapeutics, Inc. Insider Trading Activity - Stock Titan
Century Therapeutics, Inc. Updates on Cell Therapy Developments - TradingView — Track All Markets
IPS Cell-Derived Platelets Market to Rise at 9.6% CAGR Through 2025-2031: Industry and Companies Analysis Featuring Megakaryon, Xueji Shengwu, Renerval, Help, Cynata, Fate, and Century TherapeuticsResearchAndMarkets.com - Markets Financial Content
Century Therapeutics’ Long-Term Follow-Up Study: Key Insights for Investors - MSN
Century Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Century Therapeutics director reports zero beneficial share ownership | IPSC SEC FilingForm 3 - Stock Titan
Fed Meeting: Why Century Therapeutics Inc stock attracts global investorsGap Down & Expert Approved Momentum Ideas - moha.gov.vn
Century Therapeutics appoints two new board members By Investing.com - Investing.com Australia
Century Therapeutics Appoints Dr. Han Lee and Dr. Martin Murphy To Board - citybiz
Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors - Yahoo Finance
Century Therapeutics appoints two new board members - Investing.com
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors - The Manila Times
Century Therapeutics Appoints Dr. Han Lee and Dr. Martin Murphy to Board of Directors - Quiver Quantitative
Century Therapeutics Appoints Accomplished Biotechnology - GlobeNewswire
Officer Russotti Files To Sell 526 Of Century Therapeutics Inc [IPSC] - TradingView — Track All Markets
Century Therapeutics (IPSC) price target decreased by 20.00% to 4.08 - MSN
Century Therapeutics Announces Strategic Pipeline Shift and 2024 Financial Results - MSN
Will Century Therapeutics Inc. stock outperform international peersMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
What analysts say about APA Corporation stockMarket Sentiment Report & Enter Your Email to Get Stock Alerts - earlytimes.in
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Century Therapeutics 'moving with urgency' to develop drug for Type 1 diabetes - The Business Journals
There is no way Century Therapeutics Inc (IPSC) can keep these numbers up - Setenews
Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes - MSN
IPSC 2026 special meeting to vote on Nasdaq-driven reverse split - Stock Titan
Century Therapeutics Executive Acquires 35,000 Shares - TradingView
Chmn Pfeiffenberger Buys 35,000 ($17.3K) Of Century Therapeutics Inc [IPSC] - TradingView
Officer Cowan Files To Sell 5,462 Of Century Therapeutics Inc [IPSC] - TradingView
Research Analysts Set Expectations for IPSC FY2025 Earnings - Defense World
Century Therapeutics Inc. stock momentum explainedMarket Performance Recap & Weekly Stock Performance Updates - newser.com
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):